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This article reports 3 occurrences of bisphosphonate-associated atypical femur fractures as an etiology of periprosthetic hip pain in the total hip arthroplasty (THA) patient. These fractures are particularly concerning because these patients are often not advised to protect their weight bearing simply due to a painful THA and may sustain a catastrophic failure if not followed closely. Several theories have been suggested concerning the pathophysiology of atypical low-energy subtrochanteric fractures following bisphosphonate use. Each patient described in this article carried a diagnosis of rheumatoid arthritis and underwent chronic medical therapy; each patient experienced a delay in the diagnosis and onset of therapy due to low suspicion for bisphosphonateassociated fracture. This problem may become more common in the clinical setting; therefore, one must be vigilant and aware of this etiology of periprosthetic hip pain.
O steoporotic fractures pose a signifi cant health concern for postmenopausal women. Bisphosphonate therapy has been shown to decrease the risk of these fractures. 1 The bisphosphonate alendronate was approved by the US Food and Drug Administration for use in the United States in 1995, 2 but questions have recently arisen concerning low-energy subtrochanteric femur fractures sustained by chronic users. Although no defi nitive association or causality between bisphosphonates and these fractures has been established, numerous cautionary reports exist concerning the duration of use and safety of alendronate in osteoporotic patients. [3] [4] [5] Many postmenopausal women who have undergone total hip arthroplasty (THA) take bisphosphonates to treat their osteoporosis. Unfortunately, on occasion these patients present with thigh or hip pain following THA. Multiple etiologies must be considered by the evaluating physician, including loosening, sepsis, synovitis, or referred radicular pain. To our knowledge, the percentage of patients concurrently prescribed bisphosphonates and undergoing THA has not been described; however, in our clinical experience, the percentage seems to be increasing as osteoporosis is being more aggressively treated both by primary care physicians and orthopedic surgeons.
This article describes another etiology of postoperative hip pain following THA: bisphosphonate-induced subtrochanteric stress fracture. The patients described here were informed that their case data would be submitted for publication, and they gave their consent. Institutional Review Board approval was obtained.
CASE REPORTS

Patient 1
A 52-year-old woman with rheumatoid arthritis underwent a proximal femoral osteotomy with lateral plate fi xation for hip dysplasia in 1973. This was followed by a conversion THA and hardware removal without complications in 2007. The patient was asymptomatic until July 2010, when she presented to her primary care physician reporting back pain and radiating left leg pain. She was referred to a physiatrist, who obtained negative hip radiographs and spine radiographs depicting degenerative joint disease at L4-5. A left sacroiliac joint injection and a left L5 nerve root block was performed with some relief for her back and leg pain.
In October 2010, she presented to her THA surgeon reporting pain in her upper thigh that had intensifi ed over the past 2 months and required 2 crutches for ambulation. She reported no rest pain or trauma at that time. She had used nonsteroidal anti-infl ammatory drugs, analgesics, ice, heat, and a transcutaneous electrical nerve stimulation unit over the past 2 months unsuccessfully to control her symptoms. Radiographs at that time were interpreted as negative except for residual periostitis distal to the implant, felt to be related to the hardware removal ( Figure 1A ). Her pain was felt to be radicular in nature by the THA surgeon, who referred her back to the physiatrist for a L3 nerve root block, which was performed in October 2010 without relief. A bone scan was interpreted as positive for femoral loosening ( Figure 1B) .
At this time, she was referred to our hip and knee center for a second opinion. She was noted to have signifi cant pain to forceful rotation of the hip, palpatory pain along the lateral aspect of her femur, and negative stretch signs for radiculopathy. Her gait was antalgic, even with the use of a single crutch. Medications at presentation included alendronate, diclofenac, prednisone, and azathioprine, all of which she had been taking for a minimum of 5 years. Radiographs taken to include the femur distal to the implant showed an anterolateral stress fracture below the prosthesis ( Figure 1C ). 
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The patient was instructed to discontinue alendronate and begin calcium 500 mg 3 times/day and vitamin D 2000 IU/ day and continue with limited weight bearing with 2 crutches. After 8 weeks of this treatment, her pain improved, and she was weaned from crutches to a cane. At 6-month follow-up, she was asymptomatic and weaning completely from her cane.
Patient 2
In May 2010, an 85-year-old woman who underwent THA in 1995 sustained a fall onto her left side, injuring her ribs. Three weeks after her fall, she presented to her primary care physician with new-onset right hip pain. Negative radiographs were taken, and a diagnosis of trochanteric bursitis was made. She was treated with physical therapy and ultrasound to the area.
In July 2010, she was referred to our hip and knee center reporting painful THA. Physical examination at that time included an antalgic gait, tenderness over the trochanter, and mild pain with rotation of the hip. Negative radiographs were taken (Figure 2A) , and a presumptive diagnosis of an occult pelvic or trochanteric fracture was made. The patient was placed on a walker with limited weight bearing and asked to return for follow-up radiographs in 3 weeks. She subsequently saw her rheumatologist, and a bone scan was positive for a diaphyseal stress fracture ( Figure 2B ).
She was then referred back to our center, where radiographs depicted a subtrochanteric stress fracture ( Figure 2C ). Her medications at this time included prednisone, risedronate, and methotrexate; they had been taken for many years, but the patient was unable to recollect the exact timing of medication initiation. The patient was instructed to discontinue risedronate and begin calcium, vitamin D, and protective weight bearing with a walker. She was also started on teriparatide by her rheumatologist.
At 6-month follow-up, the patient's pain was minimal, and she had returned to her previous household ambulatory activity level with the use of a walker for stability.
Patient 3
A 79-year-old woman who underwent left THA in 1991 presented in November 2009 with new-onset left hip pain of approximately 1 month's duration. Medical history was signifi cant for rheumatoid arthritis and osteoporosis. Medications taken by the patient included prednisone, hydroxychloroquine, and alendronate, each for at least 9 years; however, the patient could not recollect the exact timing of medication initiation. The patient ambulated with a new limp, and tenderness was elicited with palpation over the lateral thigh. Radiographs showed a lateral cortex fracture consistent with bisphosphonate use ( Figure 3A) . She was limited in her weight bearing and was asked to use a walker at all times. Alendronate was discontinued, and a 3-month course of teriparatide initiated.
At 3-month follow-up, the patient showed improvement and was given 1 additional month of teriparatide. At 6-month follow-up, she no longer required any assistive devices for ambulation and reported no pain in her left hip. Radiographs showed evidence of a healed fracture ( Figure 3B ). Eighteen months following diagnosis, the patient was pain free with no additional interventions required.
DISCUSSION
Painful THA can be a diagnostic dilemma in some patients. As described by Hanssen, 6 it is crucial to fi rst elucidate whether the pain is from an intrinsic (the hip itself) or extrinsic (referred) source. Extrinsic sources include spinal pathology, neurologic compression, vascular disease, tendonitis, or bursitis about the hip. Intrinsic sources include loosening or fracture of the prosthesis, hip instability, prosthesis impingement, modulus of elasticity mismatch, metal hypersensitivity, wear debris with associated synovitis, or infection. 6 We add bisphosphonate-associated fracture to the list of etiologies to be considered in the workup of the painful THA. 
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It is important to note worsening symptoms in patients with painful THAs who also take bisphosphonates. This is particularly concerning because these patients are often not advised to protect their weight bearing simply due to a painful THA and may sustain a catastrophic failure if not followed closely.
A recent study by Capeci and Tejwani 7 concerning alendronate-associated femur fractures suggested radiographs of the contralateral femur and consideration of discontinuing alendronate in consultation with an endocrinologist. In these cases, protected weight bearing and cessation of alendronate was suffi cient to alleviate the symptoms and promote fracture healing. More experience with this type of fracture is needed to determine whether this is adequate treatment or if prophylactic fi xation should be recommended. However, in these cases, unlike the treatment of a virgin femur, spanning intramedullary prophylactic fi xation is not an option, and treatment may require a much more invasive procedure such as plate fi xation or stem revision. The key point in management of these patients is recognition before a catastrophic displaced fracture occurs. Atypical subtrochanteric femur fractures in association with bisphosphonate use have been described in numerous case reports and case-control studies. 3 5 These commonalities seen with atypical femur fractures were described further in a 2010 task force report of the American Society for Bone and Mineral Research to standardize these fractures for the purpose of reporting their incidence and future research. 12 Another study by Nieves et al 13 in 2010 found the rate of subtrochanteric and femoral shaft fractures to be higher than that of other fractures in women taking oral bisphosphonates. The Fracture Intervention Trial study reported by Black et al 14 in 1996 reported no signifi cant increase in the risk of subtrochanteric/diaphyseal fractures with alendronate use when compared with placebo; however, interpretation was diffi cult due to the paucity of fractures and large confi dence intervals.
Several theories have been suggested concerning the pathophysiology of atypical low-energy subtrochanteric fractures following bisphosphonate use. Bisphosphonate treatment reduces bone turnover, with resultant increased overall mineralization leading to a homogenous bone structure. Homogenous bone has been shown to have greater risk of fracture compared with more heterogeneous bone. 15, 16 Reduced bone turnover also increases the accumulation of microdamage, which subsequently reduces bone toughness and increases susceptibility of new cracks. 17, 18 Odvina et al 19 also reported markedly suppressed bone formation with reduced or absent osteoblastic surface in alendronate-treated patients presenting with spontaneous nonvertebral fractures.
The mechanism of action associated with the bisphosphonates alendronate and residronate, as well as osteopromotors such as teriparatide, deserves mention. Bisphosphonates show preferential localization to sites of bone resorption, specifically inhibiting the ruffl ed border active in resorption of bone by osteoclasts. In contrast, teriparatide is a recombinant human parathyroid hormone that directly stimulates osteoblastogenesis and inhibits osteoblast apoptosis. Additional physiologic actions include promoting renal tubular reabsorption of calcium and phosphate and intestinal calcium absorption. 2, 20 The number of atypical subtrochanteric fractures in association with bisphosphonates has been estimated to be as high as 1 per 1000 per year, which provides a favorable risk-benefi t ratio for the use of bisphosphonates in the treatment and prevention of osteoporosis. 21 Bisphosphonates should not be discontinued for patients at risk of osteoporotic fragility fractures; however, prescribers should be aware of the possible associations linked to their use.
We recommend that our patients suspend all bisphosphonate use to allow the fracture to heal and hopefully prevent a contralateral fracture. Current endocrinology literature suggests that patients at mild fracture risk might stop bisphosphonate treatment after 5 years and remain off as long as bone mineral density is stable. Higher risk patients treated for 10 years may undergo a holiday of no more than 1 or 2 years with continued nonbisphospho- 
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nate therapy during that time. 22 The patients described herein would most likely fall into the high-risk category, making their long duration of bisphosphonate therapy appropriate; however, restarting their therapy in the future will be an issue of timing and concerns for using the same agent. Changing to an osteopromoting drug such as teriparatide may be an option in these high-risk patients.
In a recent report, the median bisphosphonate treatment duration in patients with atypical subtronchanteric and femoral shaft fractures was 7 years.
14 Recommendations were made for patients sustaining a recent fracture and with femoral neck T-scores ϾϪ2.5 in consideration of a drug holiday from the bisphosphonate. The benefi t of discontinuation after 4 to 5 years in the low-risk patient is still unknown. No data exist to guide when therapy should be reinstituted; however, the study recommended following patients with clinical assessment, bone turnover markers, and bone mineral density determination following resolution of the fracture. 14 Compliance with bisphosphonate therapy by the patients in our series was high. Each patient required relatively strict adherence to her medication protocols due to other medical cormorbidities, resulting in regimented medication schedules. This is in stark contrast to a study by Siris et al 23 that showed 43% refi ll compliance in patients taking bisphosphonates and only 20% of patients receiving continuous, gap-free coverage for a 2-year period. However, those patients with strict adherence to bisphosphonate therapy were shown to have relative risk reductions of 20% to 45% for osteoporotic fractures. 23 Interestingly, each of our patients carried a diagnosis of rheumatoid arthritis and underwent chronic medical therapy that included prednisone in addition to methotrexate, azathioprine, or hydroxychloroquine. It is well known that osteoporosis may occur with chronic infl ammatory diseases, and risk is further increased with exposure to glucocorticoids. A study by Girgis et al 12 showed an increased risk (odds ratio, 5.2) of subtrochanteric fracture in patients on both a bisphosphonate and glucocorticoids. Patients using glucocorticoids have fractures at higher bone density than those not using glucocorticoids. 24 In a study by Saag et al, 25 bone density increased in patients receiving either alendronate or teriparatide, despite continued treatment with glucocorticoids. In steroid users, the bone density with teriparatide was signifi cantly better than alendronate. Teriparatide was therefore recommended in patients at high risk for fracture who required sustained use of glucocorticoids and who had either osteoporosis or low bone mass with a prevalent fracture. 25 Any of the patients presented herein would likely qualify as high risk and may have experienced greater benefi t from teriparatide than alendronate therapy.
Unfortunately, our patients experienced a delay in the diagnosis and onset of therapy due to low suspicion. Fortunately, each was diagnosed prior to catastrophic fracture around the implant, which would have necessitated a more invasive surgical intervention. Regarding physical examination, each patient had specifi c pain in the proximal lateral thigh with initially negative radiographs. Two of the patients also underwent 3-phase technetium bone scans that clearly defi ned the site of fracture within the femur and confi rmation of radiographic fi ndings at the diagnostic follow-up visit. Earlier investigation with a bone scan may have provided a diagnosis sooner; however, this depends on clinical insight and availability.
While early detection may be diffi cult, high suspicion and awareness of this entity in patients taking bisphosphonates may aid in the diagnosis and treatment of this problem. This is further stressed in the 2010 recommendations that education of physicians and patients concerning the prodromal symptoms of thigh or groin pain may catch these impending fractures prior to catastrophic failure. 26 Physicians should also ask patients on bisphosphonates and other potent antiresorptive agents such as glucocorticoids about thigh or groin pain. Plain radiographs should be used for initial assessment; however, if equivocal, more specifi c testing such as magnetic resonance imaging or bone scan should be considered if index of suspicion remains high. 26 
